Beigene Has Appointed Aaron Rosenberg As Chief Financial Officer, Effective July 22 Succeeding Julia Wang, Who Is Departing To Pursue External Opportunities And Will Stay With The Company Through August To Support The Transition

7/18/24 6:40:19 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $BGNE alert in real time by email

Get the next $BGNE alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$BGNE

Date	Price Target	Rating	Analyst
9/18/2024	$288.00	Mkt Outperform	JMP Securities
2/6/2024	$185.00	Overweight	JP Morgan
9/12/2023	$259.00	Outperform	Macquarie
8/17/2023	$287.00	Buy	Jefferies
7/17/2023	$275.00	Buy	Citigroup
6/30/2023	$335.00 → $196.00	Outperform → Mkt Perform	Bernstein
1/12/2023	$308.00	Buy	Daiwa Securities
10/13/2022	$205.00	Neutral → Buy	Guggenheim

More analyst ratings

$BGNE
Leadership Updates

Live Leadership Updates

Labcorp CFO Glenn Eisenberg Announces Plans to Retire
Julia Wang Named Chief Financial Officer Beginning December 2, 2024 BURLINGTON, N.C., Nov. 19, 2024 /PRNewswire/ -- Labcorp (NYSE:LH), a global leader of innovative and comprehensive laboratory services, announced today that Executive Vice President and Chief Financial Officer (CFO) Glenn Eisenberg will retire from the company and Julia Wang will join on December 2, 2024, as Executive Vice President and Chief Financial Officer. Mr. Eisenberg will remain at Labcorp as Special Advisor to the CEO through April 2025 to ensure a seamless transition of his current role and assist with strategic initiatives underway within the company.
11/19/24 7:00:00 AM ET
$BGNE
$LH
Biotechnology: Pharmaceutical Preparations
Health Care
Medical Specialities
Global Oncology Innovator BeiGene Appoints Shalini Sharp to Board of Directors
BeiGene, Ltd. (NASDAQ:BGNE, HKEX: 06160, SSE: 688235))), a global oncology company, today announced the appointment of Shalini Sharp to its Board of Directors and as a member of the Board's Audit Committee, effective September 27, 2024. "We are fortunate to welcome Shalini to the Board of Directors at this pivotal moment of growth," said John V. Oyler, Co-Founder, Chairman and CEO of BeiGene. "The Board is looking forward to collaborating with Shalini, whose extensive experience in leading innovative global pharmaceutical companies will be invaluable as we enter new markets, advance our pipeline of groundbreaking cancer therapies, and embark on a transformative growth phase. Her financial
9/26/24 6:00:00 AM ET
$BGNE
Biotechnology: Pharmaceutical Preparations
Health Care
BeiGene Announces Updates to Commercial Leadership Team
BeiGene, Ltd. (NASDAQ:BGNE, HKEX: 06160, SSE: 688235))), a global oncology company, today announced the appointment of Matt Shaulis as General Manager of North America, effective September 25. "We are excited to welcome Matt, who brings a wealth of global pharmaceutical experience, including leading the commercialization of blockbuster franchises at multiple multinational companies," said John V. Oyler, Co-Founder, Chairman and CEO at BeiGene. "Matt's management will be pivotal as we continue our leadership in hematology with BRUKINSA and replicate that success in solid tumors, with a deep and exciting pipeline of innovative therapies." Mr. Shaulis is a global commercial executive with ov
9/9/24 7:00:00 AM ET
$BGNE
Biotechnology: Pharmaceutical Preparations
Health Care

Labcorp CFO Glenn Eisenberg Announces Plans to Retire
Julia Wang Named Chief Financial Officer Beginning December 2, 2024 BURLINGTON, N.C., Nov. 19, 2024 /PRNewswire/ -- Labcorp (NYSE:LH), a global leader of innovative and comprehensive laboratory services, announced today that Executive Vice President and Chief Financial Officer (CFO) Glenn Eisenberg will retire from the company and Julia Wang will join on December 2, 2024, as Executive Vice President and Chief Financial Officer. Mr. Eisenberg will remain at Labcorp as Special Advisor to the CEO through April 2025 to ensure a seamless transition of his current role and assist with strategic initiatives underway within the company.
11/19/24 7:00:00 AM ET
$BGNE
$LH
Biotechnology: Pharmaceutical Preparations
Health Care
Medical Specialities
BeiGene Announces Settlement of Litigation Against Generic Filer of BRUKINSA
Agreement provides for generic entry of innovative BTK inhibitor in 2037 BeiGene, Ltd. (NASDAQ:BGNE, HKEX: 06160, SSE: 688235)), a global oncology company which intends to change its name to BeOne Medicines Ltd., today announced it has entered into a settlement agreement with MSN Pharmaceuticals, Inc. and MSN Laboratories Private Ltd. resolving patent litigation related to MSN's Abbreviated New Drug Application (ANDA) seeking approval to market a generic version of BRUKINSA® (zanubrutinib) in the U.S. Under the terms of the agreement, MSN will not be able to sell a generic version of BRUKINSA earlier than June 15, 2037, subject to potential acceleration or extension under certain custom
11/19/24 6:00:00 AM ET
$BGNE
Biotechnology: Pharmaceutical Preparations
Health Care
BeiGene Unveils Proposed Name Change to BeOne Medicines, Reaffirming Its Mission to Unite Global Community Against Cancer
New name reflects Company's bold vision to eradicate cancer by harnessing the transformative power of global collaboration and multisectoral partnerships Company will change its Nasdaq ticker to ONC BeiGene, Ltd. (NASDAQ:BGNE, HKEX: 06160, SSE: 688235)), a global oncology company, today announced its intent to change the Company's name to BeOne Medicines Ltd., confirming its commitment to develop innovative medicines to eliminate cancer by partnering with the global community to serve as many patients as possible. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241114671168/en/(Graphic: Business Wire) "Cancer, a leading ca
11/14/24 6:00:00 AM ET
$BGNE
Biotechnology: Pharmaceutical Preparations
Health Care

$BGNE
Financials

Live finance-specific insights

BeiGene and DualityBio Announce Partnership to Advance Differentiated Antibody Drug Conjugate (ADC) Therapy for Solid Tumors
BeiGene acquires exclusive option for global license to investigational antibody drug conjugate; DualityBio to continue preclinical research activities and support Investigational New Drug filing BeiGene (NASDAQ:BGNE, HKEX: 06160, SSE: 688235))), a global biotechnology company, and DualityBio, a next-generation ADC company, today announced an agreement for BeiGene to acquire an exclusive option for a global clinical and commercial license to an investigational, preclinical ADC therapy for patients with select solid tumors. "With one of the industry's leading global oncology research teams, we are investing in highly impactful therapeutic modalities such as ADCs that complement our dynam
7/10/23 7:00:00 AM ET
$BGNE
Biotechnology: Pharmaceutical Preparations
Health Care
BeiGene's BRUKINSA® (zanubrutinib) Demonstrated Superior Progression-Free Survival Over IMBRUVICA® (ibrutinib) in Chronic Lymphocytic Leukemia in Late-Breaker at ASH
Final ALPINE Progression-Free Survival (PFS) results simultaneously published in The New England Journal of Medicine and presented at late-breaking session at 64th American Society of Hematology Annual Meeting BRUKINSA demonstrated superiority to IMBRUVICA in both PFS and Overall Response Rate with fewer cardiac events BeiGene (NASDAQ:BGNE, HKEX: 06160, SSE: 688235))) a global biotechnology company, today presented the final progression-free survival (PFS) analysis of the ALPINE trial demonstrating superior efficacy and a favorable cardiac safety profile for patients receiving BRUKINSA® as compared to IMBRUVICA® in a global phase 3 trial in patients with relapsed/refractory (R/R) chronic
12/13/22 10:00:00 AM ET
$BGNE
Biotechnology: Pharmaceutical Preparations
Health Care
BeiGene to Host Investor Conference Call and Webcast to Discuss the Company's Early Development Pipeline and Research on August 25, 2021
BeiGene, Ltd. (NASDAQ:BGNE, HKEX: 06160))), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, today announced that it will host an investor conference call and webcast on Wednesday, August 25, 2021, at 9:30 a.m. ET to discuss the Company's early development pipeline and research. A live webcast of the conference call can be accessed from the investors section of BeiGene's website at http://ir.beigene.com or http://hkexir.beigene.com. An archived replay will be available after the event for 90 days. About BeiGene BeiGene is a global, science-driven biotechnology company
8/16/21 7:00:00 AM ET
$BGNE
Biotechnology: Pharmaceutical Preparations
Health Care

Beigene Has Appointed Aaron Rosenberg As Chief Financial Officer, Effective July 22 Succeeding Julia Wang, Who Is Departing To Pursue External Opportunities And Will Stay With The Company Through August To Support The Transition

Chat with this insight

Recent Analyst Ratings for $BGNE

$BGNE Leadership Updates

Live Leadership Updates

Labcorp CFO Glenn Eisenberg Announces Plans to Retire

Global Oncology Innovator BeiGene Appoints Shalini Sharp to Board of Directors

BeiGene Announces Updates to Commercial Leadership Team

$BGNE SEC Filings

BeiGene Ltd. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

BeiGene Ltd. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

Amendment: SEC Form SCHEDULE 13D/A filed by BeiGene Ltd.

$BGNE Press Releases

Fastest customizable press release news feed in the world

$BGNE Market Insights

Live Market Insights

Labcorp CFO Glenn Eisenberg Announces Plans to Retire

BeiGene Announces Settlement of Litigation Against Generic Filer of BRUKINSA

BeiGene Unveils Proposed Name Change to BeOne Medicines, Reaffirming Its Mission to Unite Global Community Against Cancer

BeiGene Opens U.S. Biologics Manufacturing And Clinical R&D Facility In New Jersey With $800M Investment

Beigene Has Appointed Aaron Rosenberg As Chief Financial Officer, Effective July 22 Succeeding Julia Wang, Who Is Departing To Pursue External Opportunities And Will Stay With The Company Through August To Support The Transition

BeiGene shares are trading lower after B of A Securities maintained a Neutral rating on the stock and lowered its price target from $180 to $152.5

$BGNE Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Chief Executive Officer Oyler John sold $3,756,092 worth of American Depositary Shares (16,175 units at $232.22), closing all direct ownership in the company (SEC Form 4)

Director Sharp Shalini was granted 8,151 units of Ordinary Shares (SEC Form 4)

SEC Form 3 filed by new insider Sharp Shalini

$BGNE Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

JMP Securities initiated coverage on BeiGene with a new price target

JP Morgan resumed coverage on BeiGene with a new price target

Macquarie initiated coverage on BeiGene with a new price target

$BGNE Financials

Live finance-specific insights

BeiGene and DualityBio Announce Partnership to Advance Differentiated Antibody Drug Conjugate (ADC) Therapy for Solid Tumors

BeiGene's BRUKINSA® (zanubrutinib) Demonstrated Superior Progression-Free Survival Over IMBRUVICA® (ibrutinib) in Chronic Lymphocytic Leukemia in Late-Breaker at ASH

BeiGene to Host Investor Conference Call and Webcast to Discuss the Company's Early Development Pipeline and Research on August 25, 2021

$BGNE Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13D/A filed by BeiGene Ltd.

SEC Form SC 13G/A filed by BeiGene Ltd. (Amendment)

SEC Form SC 13G/A filed by BeiGene Ltd. (Amendment)

Recent Analyst Ratings for
$BGNE

$BGNE
Leadership Updates

$BGNE
SEC Filings

$BGNE
Press Releases

$BGNE
Market Insights

$BGNE
Insider Trading

$BGNE
Analyst Ratings

$BGNE
Financials

$BGNE
Large Ownership Changes